Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells $61,725.12 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 678 shares of the stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $91.04, for a total value of $61,725.12. Following the completion of the sale, the director owned 685,393 shares in the company, valued at approximately $62,398,178.72. The trade was a 0.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Bruce Booth also recently made the following trade(s):

• On Thursday, December 11th, Bruce Booth sold 6,101 shares of Kymera Therapeutics stock. The shares were sold at an average price of $91.23, for a total value of $556,594.23.
• On Wednesday, December 10th, Bruce Booth sold 229,809 shares of Kymera Therapeutics stock. The shares were sold at an average price of $91.73, for a total value of $21,080,379.57.

Kymera Therapeutics Trading Up 2.1%

NASDAQ:KYMR opened at $89.68 on Monday. The company has a market cap of $6.45 billion, a price-to-earnings ratio of -24.98 and a beta of 2.28. Kymera Therapeutics, Inc. has a twelve month low of $19.44 and a twelve month high of $103.00. The stock has a fifty day simple moving average of $64.77 and a 200-day simple moving average of $52.18.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.19). Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%.The company had revenue of $2.76 million during the quarter, compared to analysts’ expectations of $23.15 million. As a group, equities research analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on KYMR. Wells Fargo & Company lifted their price target on shares of Kymera Therapeutics from $69.00 to $116.00 and gave the company an “overweight” rating in a research note on Tuesday, December 9th. Jefferies Financial Group lifted their target price on Kymera Therapeutics from $73.00 to $122.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Oppenheimer increased their price target on Kymera Therapeutics from $67.00 to $120.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 9th. Wall Street Zen upgraded Kymera Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Finally, UBS Group upgraded shares of Kymera Therapeutics to a “strong-buy” rating in a report on Thursday, December 4th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $112.80.

Hedge Funds Weigh In On Kymera Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC lifted its position in shares of Kymera Therapeutics by 642.9% during the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock valued at $27,000 after buying an additional 540 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in Kymera Therapeutics by 506.6% during the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after acquiring an additional 770 shares during the last quarter. Larson Financial Group LLC boosted its stake in Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after acquiring an additional 349 shares in the last quarter. Osaic Holdings Inc. grew its holdings in Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares during the last quarter. Finally, Bessemer Group Inc. increased its position in shares of Kymera Therapeutics by 652.0% during the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after purchasing an additional 815 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.